SCHEMBL13099493

SCHEMBL13099493

COc1ccc(CN2CC[C@H]3C=CC[C@@H](C(=O)O)[C@H]3C2=O)cc1OC

nearest known ligand 0.65

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ HCRTR1 O43613 2/20 0.65
▸ ALDH1A1 P00352 3/20 0.63
▸ KMT2A Q03164 3/20 0.49
▸ MEN1 O00255 2/20 0.49
▸ OPRK1 P41145 2/20 0.49
▸ HSD17B10 Q99714 1/20 0.47
▸ CA1 P00915 2/20 0.47
▸ CA2 P00918 2/20 0.47
▸ CA9 Q16790 2/20 0.47
▸ CA12 O43570 1/20 0.47
▸ PREP P48147 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ MAPK1 P28482 1/20 0.41
▸ SIGMAR1 Q99720 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13108667 1.00 HCRTR1 (0.65) HCRTR1ALDH1A1KMT2AMEN1OPRK1
SCHEMBL13397599 1.00 HCRTR1 (0.65) HCRTR1ALDH1A1KMT2AMEN1OPRK1
SCHEMBL13108594 0.86 HCRTR1 (0.59) HCRTR1ALDH1A1KMT2AMEN1OPRK1
SCHEMBL13099513 0.86 HCRTR1 (0.59) HCRTR1ALDH1A1KMT2AMEN1OPRK1
SCHEMBL15978272 0.82 ALDH1A1 (0.78) HCRTR1ALDH1A1KMT2AMEN1OPRK1
SCHEMBL3264452 0.82 ALDH1A1 (0.78) HCRTR1ALDH1A1KMT2AMEN1OPRK1
SCHEMBL13099472 0.82 ALDH1A1 (0.78) HCRTR1ALDH1A1KMT2AMEN1OPRK1
SCHEMBL13108582 0.82 ALDH1A1 (0.78) HCRTR1ALDH1A1KMT2AMEN1OPRK1
SCHEMBL13108370 0.82 ALDH1A1 (0.78) HCRTR1ALDH1A1KMT2AMEN1OPRK1
SCHEMBL13108434 0.82 HCRTR1 (0.63) HCRTR1ALDH1A1KMT2AMEN1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140243333-A1 SYNTHESIS OF FUNCTIONALIZED OCTAHYDRO-ISOQUINOLIN-1-ONE-8-CARBOXYLIC ESTERS AND ANALOGS, AND THERAPEUTIC METHODS UNIVERSITY OF KANSAS (US) 2014-08-28 — — US disclosed
US-20140243333-A1 SYNTHESIS OF FUNCTIONALIZED OCTAHYDRO-ISOQUINOLIN-1-ONE-8-CARBOXYLIC ESTERS AND ANALOGS, AND THERAPEUTIC METHODS UNIVERSITY OF KANSAS (US) 2014-08-28 — — US disclosed
US-8735391-B2 Synthesis of functionalized octahydro-isoquinolin-1-one-8-carboxamides, octahydro-isoquinolin-1-one-8-carboxylic esters and analogs, and therapeutic methods UNIVERSITY OF KANSAS (US) 2014-05-27 — — US disclosed
US-8735391-B2 Synthesis of functionalized octahydro-isoquinolin-1-one-8-carboxamides, octahydro-isoquinolin-1-one-8-carboxylic esters and analogs, and therapeutic methods UNIVERSITY OF KANSAS (US) 2014-05-27 — — US disclosed
US-20100256142-A1 SYNTHESIS OF FUNCTIONALIZED OCTAHYDRO-ISOQUINOLIN-1-ONE-8- CARBOXAMIDES, OCTAHYDRO-ISOQUINOLIN-1-ONE-8-CARBOXYLIC ESTERS AND ANALOGS, AND THERAPEUTIC METHODS UNIVERSITY OF NORTH CAROLINA 2010-10-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256142-A1 SYNTHESIS OF FUNCTIONALIZED OCTAHYDRO-ISOQUINOLIN-1-ONE-8- CARBOXAMIDES, OCTAHYDRO-ISOQUINOLIN-1-ONE-8-CARBOXYLIC ESTERS AND ANALOGS, AND THERAPEUTIC METHODS OPRM1, OPRK1, OPRL1 HCRTR1 14/4885ALDH1A1 131/4885KMT2A 903/4885
US-20140243333-A1 SYNTHESIS OF FUNCTIONALIZED OCTAHYDRO-ISOQUINOLIN-1-ONE-8-CARBOXYLIC ESTERS AND ANALOGS, AND THERAPEUTIC METHODS OPRM1, OPRK1, OPRD1 HCRTR1 33/4885ALDH1A1 109/4885KMT2A 1523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback